Abbvie 1Q Revenues: $12.3 billion (+1%) 1Q Earnings: $1.4 billion (earnings were $239 million 1Q23) Comments: Immunology portfolio sales were $5.4 billion, down 4% in the quarter. Global Humira sales were $2.3 billion down 36%. Global Skyrizi revenues were $2.0 billion, an increase of 48% and global Rinvoq revenues were $1.1 billion, an increase of 59%. Oncology portfolio sales were $1.5 billion, an increase of 9%. Global Imbruvica sales were $838 million, down 5%. Global Venclexta sales were...